小檗碱预防结直肠腺瘤复发和肿瘤发生：一项6年随访的随机临床试验。

IF 10.6 1区医学 Q1 CELL BIOLOGY

Cell Reports Medicine Pub Date : 2025-09-16 Epub Date: 2025-08-11 DOI:10.1016/j.xcrm.2025.102293

Yong-Jie Tan, Tian-Hui Zou, Ke Yu, Jian-Qiu Sheng, Peng Jin, Ming-Jie Zhang, Xiao-Ping Zou, Xiao-Tan Dou, Si-De Liu, Shao-Hui Huang, Jian-Lin Ren, Xiao-Ning Yang, Zhan-Ju Liu, Xiao-Min Sun, Bang-Mao Wang, Hai-Long Cao, Ya-Xuan Zhang, Qin-Yan Gao, Hui-Min Chen, Yun Cui, Ying-Xuan Chen, Jing-Yuan Fang

{"title":"小檗碱预防结直肠腺瘤复发和肿瘤发生：一项6年随访的随机临床试验。","authors":"Yong-Jie Tan, Tian-Hui Zou, Ke Yu, Jian-Qiu Sheng, Peng Jin, Ming-Jie Zhang, Xiao-Ping Zou, Xiao-Tan Dou, Si-De Liu, Shao-Hui Huang, Jian-Lin Ren, Xiao-Ning Yang, Zhan-Ju Liu, Xiao-Min Sun, Bang-Mao Wang, Hai-Long Cao, Ya-Xuan Zhang, Qin-Yan Gao, Hui-Min Chen, Yun Cui, Ying-Xuan Chen, Jing-Yuan Fang","doi":"10.1016/j.xcrm.2025.102293","DOIUrl":null,"url":null,"abstract":"Berberine has been reported as a safe and effective pharmacological agent to reduce colorectal adenoma recurrence after polypectomy. This retrospective cohort study is an extended follow-up of a previous clinical trial (NCT02226185) during the post-treatment observational phase. We aim to evaluate the long-term protective effects of berberine on adenoma recurrence. Among 895 patients who finished the previous 2-year randomized trial, we recruited 781 patients at 7 clinical centers across 6 provinces in China. The primary outcome is adenoma recurrence. Between December 29, 2018, and October 10, 2024, 648 patients underwent at least one colonoscopy during the follow-up. The protective effects of berberine persist for at least 6 years after treatment cessation, with lower adenoma recurrence rate (34.7% vs. 52.1%) and lower neoplasm occurrence rate (63.4% vs. 71.0%). Berberine may serve as a potential long-term preventive agent against adenoma recurrence after polypectomy.","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102293"},"PeriodicalIF":10.6000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490254/pdf/","citationCount":"0","resultStr":"{\"title\":\"Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trial.\",\"authors\":\"Yong-Jie Tan, Tian-Hui Zou, Ke Yu, Jian-Qiu Sheng, Peng Jin, Ming-Jie Zhang, Xiao-Ping Zou, Xiao-Tan Dou, Si-De Liu, Shao-Hui Huang, Jian-Lin Ren, Xiao-Ning Yang, Zhan-Ju Liu, Xiao-Min Sun, Bang-Mao Wang, Hai-Long Cao, Ya-Xuan Zhang, Qin-Yan Gao, Hui-Min Chen, Yun Cui, Ying-Xuan Chen, Jing-Yuan Fang\",\"doi\":\"10.1016/j.xcrm.2025.102293\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Berberine has been reported as a safe and effective pharmacological agent to reduce colorectal adenoma recurrence after polypectomy. This retrospective cohort study is an extended follow-up of a previous clinical trial (NCT02226185) during the post-treatment observational phase. We aim to evaluate the long-term protective effects of berberine on adenoma recurrence. Among 895 patients who finished the previous 2-year randomized trial, we recruited 781 patients at 7 clinical centers across 6 provinces in China. The primary outcome is adenoma recurrence. Between December 29, 2018, and October 10, 2024, 648 patients underwent at least one colonoscopy during the follow-up. The protective effects of berberine persist for at least 6 years after treatment cessation, with lower adenoma recurrence rate (34.7% vs. 52.1%) and lower neoplasm occurrence rate (63.4% vs. 71.0%). Berberine may serve as a potential long-term preventive agent against adenoma recurrence after polypectomy.\",\"PeriodicalId\":9822,\"journal\":{\"name\":\"Cell Reports Medicine\",\"volume\":\" \",\"pages\":\"102293\"},\"PeriodicalIF\":10.6000,\"publicationDate\":\"2025-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490254/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell Reports Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.xcrm.2025.102293\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Reports Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.xcrm.2025.102293","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

小檗碱是一种安全有效的减少息肉切除术后结直肠腺瘤复发的药物。这项回顾性队列研究是对先前临床试验（NCT02226185）在治疗后观察期的扩展随访。我们的目的是评估小檗碱对腺瘤复发的长期保护作用。在完成前2年随机试验的895名患者中，我们在中国6个省的7个临床中心招募了781名患者。主要结果是腺瘤复发。在2018年12月29日至2024年10月10日期间，648名患者在随访期间至少接受了一次结肠镜检查。小檗碱的保护作用在停止治疗后至少持续6年，腺瘤复发率较低（34.7%比52.1%），肿瘤发生率较低（63.4%比71.0%）。小檗碱可能作为一种潜在的长期预防息肉切除术后腺瘤复发的药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trial.

Berberine has been reported as a safe and effective pharmacological agent to reduce colorectal adenoma recurrence after polypectomy. This retrospective cohort study is an extended follow-up of a previous clinical trial (NCT02226185) during the post-treatment observational phase. We aim to evaluate the long-term protective effects of berberine on adenoma recurrence. Among 895 patients who finished the previous 2-year randomized trial, we recruited 781 patients at 7 clinical centers across 6 provinces in China. The primary outcome is adenoma recurrence. Between December 29, 2018, and October 10, 2024, 648 patients underwent at least one colonoscopy during the follow-up. The protective effects of berberine persist for at least 6 years after treatment cessation, with lower adenoma recurrence rate (34.7% vs. 52.1%) and lower neoplasm occurrence rate (63.4% vs. 71.0%). Berberine may serve as a potential long-term preventive agent against adenoma recurrence after polypectomy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cell Reports Medicine Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)

CiteScore

15.00

自引率

1.40%

发文量

231

审稿时长

40 days

期刊介绍： Cell Reports Medicine is an esteemed open-access journal by Cell Press that publishes groundbreaking research in translational and clinical biomedical sciences, influencing human health and medicine. Our journal ensures wide visibility and accessibility, reaching scientists and clinicians across various medical disciplines. We publish original research that spans from intriguing human biology concepts to all aspects of clinical work. We encourage submissions that introduce innovative ideas, forging new paths in clinical research and practice. We also welcome studies that provide vital information, enhancing our understanding of current standards of care in diagnosis, treatment, and prognosis. This encompasses translational studies, clinical trials (including long-term follow-ups), genomics, biomarker discovery, and technological advancements that contribute to diagnostics, treatment, and healthcare. Additionally, studies based on vertebrate model organisms are within the scope of the journal, as long as they directly relate to human health and disease.